Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab.
about
Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphomaMonoclonal antibodies in acute lymphoblastic leukemiaAlemtuzumab for B-cell chronic lymphocytic leukemia.Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signalingSpecific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv.Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathwaysEndogenous neurotrophins and Trk signaling in diffuse large B cell lymphoma cell lines are involved in sensitivity to rituximab-induced apoptosis.Burkitt lymphoma: pathogenesis and immune evasion.Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cellsAnti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.Treatment of systemic lupus erythematosus with epratuzumab.Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus.CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas.Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphomaEpratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II studyCell death signaling and anticancer therapyTreating Sjögren's Syndrome: Insights for the ClinicianBispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action.Internalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosusEpratuzumab in the therapy of oncological and immunological diseases.Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies.B cell modulation in rheumatologyB-cell targeting: a novel approach to immune intervention today and tomorrow.Targeting of the immune system in systemic lupus erythematosus.Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody.Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma.Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials.A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate.Cancer therapeutic antibodies come of age: targeting minimal residual disease.Emerging therapies for B-cell non-Hodgkin lymphoma.Antibody-based therapy of leukaemia.Therapy of Philadelphia chromosome-negative acute lymphoblastic leukemia in adults: new paradigms.Diversity in antibody-based approaches to non-Hodgkin lymphoma.The future role of monoclonal antibody therapy in childhood acute leukaemias.CD22 and autoimmune disease.Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.The role of monoclonal antibodies in the treatment of lymphomas.
P2860
Q24633714-91A8F94E-394E-495D-87A2-C977FF39F435Q27022540-432AAEFD-D277-4C71-9502-371CC5F71933Q33380135-CD0FA7DB-6169-4B08-8C80-305A608FC14CQ33691812-D5552B40-13A7-416A-BA0F-6CD2533C6073Q33767470-0EBCCF80-1755-4466-A070-F7629AE9273BQ33944243-87B0C23B-DF01-4783-8D2C-34824D8C6AA2Q34072659-9302C32C-F51A-49EB-A211-FEB46C3A0C20Q34189497-7E66F4D1-1D14-4302-8DEA-F3CBDC4A3FADQ34193553-87A783EB-01A0-43D6-9164-65718E25FD5DQ34463593-F450F052-2E99-4051-A2F1-7F677F5BAF5AQ34580559-1EDA50E1-31C8-4C5F-B3B2-D430C7634CE5Q34613920-D4DDB7A7-4263-44E3-A302-EC5755175BADQ34999743-9412AFE6-397F-4333-A97A-C2CE1B3B897FQ35170984-84585DEE-98E6-4DA2-BF9C-6FE2CEFB75A8Q35483564-8E775210-6E1B-4ADC-A9E1-82A8642E0DA2Q35605535-A0A9E7B9-3B21-4AD9-A470-850CFDA58E89Q35972102-02F5E458-48B8-4B37-A986-EC873512F4A8Q36056942-DE765941-F152-4A02-868B-00193A5FD5FFQ36445879-4A506F8B-9EE8-41EC-BFA9-4DECE54477A1Q36532571-F0050E4D-8CCF-40CD-BA07-E91E6FE25CFCQ36636619-F996402D-A6E0-41E2-836C-5F6BC66C876EQ36832137-C0B58CC8-C340-4AD9-8226-6367F2443114Q36878215-FAA80E0E-0A5B-43B2-8FBB-E35BD6BCDE48Q36922233-1D0662ED-2996-450A-8FF1-AE6A3A8D2D25Q37060593-02B58714-A372-4741-94E5-798F14A76AE7Q37081981-03F0F8A9-3DD2-4DEC-86B3-461131569C48Q37126126-9E55B748-96F9-4EB8-BC4F-6E522A2984AAQ37234627-ABF95E6D-CD31-4FE7-81BA-73AA3794D089Q37301320-7E04A7D4-67FA-41E6-9A29-00B6224A601BQ37308467-41E9318C-1D16-45C3-BE8A-B720E48F8CD0Q37370563-FA8DE773-4D75-42C5-A85A-E5A28E2DD8C8Q37453793-0CE9B5B4-95E9-42EE-900C-00B4169CE868Q37598947-6224B74E-7521-4AF2-B2E3-9A93027FA3C3Q37605247-8FAC0CAA-3D79-446C-9108-4855F9DAABD0Q37605864-98CEC7F2-F6D0-49DA-9A78-04EDD6BBA828Q37785097-0AB41DF6-5D5A-41F9-A93C-43E67753E97DQ38033600-7462442D-C6A0-4A33-A4CF-DD0EC3841E18Q38053491-3F91266E-6BAE-4591-969C-890DCBB752CFQ38068494-9700C9DD-C608-4719-9A7C-1CA8AA17A981Q38069595-C1B0DDE9-E78B-4E4E-9A2E-68DEAE91DCC3
P2860
Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Epratuzumab, a CD22-targeting ...... mode of action from rituximab.
@en
type
label
Epratuzumab, a CD22-targeting ...... mode of action from rituximab.
@en
prefLabel
Epratuzumab, a CD22-targeting ...... mode of action from rituximab.
@en
P2093
P1433
P1476
Epratuzumab, a CD22-targeting ...... mode of action from rituximab.
@en
P2093
Alessandra Cesano
David M Goldenberg
Hans J Hansen
Josette Carnahan
Kristen Hess
Rhona Stein
Zhengxing Qu
P304
P356
10.1016/J.MOLIMM.2006.05.007
P577
2006-06-30T00:00:00Z